ESKAYEF PHARMACEUTICALS

ABOUT

Eskayef Pharmaceuticals Ltd. is one of the leaders in Bangladesh’s pharmaceutical industry. With its presence across the world, it has earned coveted accreditations from the US FDA, UK MHRA, EU EMA, TGA Australia, and more. Eskayef spread its wings in 1990 when the Bangladeshi operations of SmithKline & French were acquired by Transcom Group.

Milestones

1979

Multinational SmithKline & French (SK&F) enters Bangladesh

1990

Transcom acquires SmithKline & French (SK&F) and becomes Eskayef Bangladesh Ltd

2017

Eskayef Bangladesh Ltd. emerges as Eskayef Pharmaceuticals Ltd. to go more global

1999

Pioneering of Pellet Technology in Bangladesh

2001

Acquisition of Squibb Plant at Tongi
Beginning of Animal Health Business

2003-2004

Beginning of International Business

2008

Accreditation by UK MHRA & EU GMP
Commissioning of Dedicated Cephalosporin Plant

2009-2010

Accreditation by TGA Australia

2011-2012

Accreditation by VMD UK
Starts manufacturing Insulin for Novo Nordisk

2013

Commissioning of Sterile Unit at Tongi
Eskayef ventures into Eyecare segments by launching Ophthalmic Drops

2014-2015

Approval by UNICEF
Acquisition of Salna Plant

2016

Commissioning of Rupganj Plant

2017

Commissioning of future-ready and state-of the art manufacturing plant, Faraaz Ayaaz Hossain Building and its accreditation by UK MHRA.
Launching of Carbapenem products from dedicated state-of-the-art facility

2018

With the mission of fighting together and winning the battle against Cancer, Eskayef launches oncology products from its dedicated Oncology plant with 1st time in Bangladesh ISOLATOR technology
Eskayef establishes its state-of the art dedicated R&D Centre at Salna

2020

Eskayef redefines its capability by introducing Remivir injection, the 1st generic Remdesivir brand in the world for treating hospitalized Covid-19 patients
Eskayef Oncology manufacturing plant receives EU GMP Approval, which is the 1st and only EU GMP certified Oncology Facility in Bangladesh

2021

Eskayef introduces Monuvir brand, the 1st Generic Molnupiravir brand in the world for the treatment of COVID-19 patients
Eskayef introduces Paxovir brand, the 1st Generic Nirmatrelvir + Ritonavir brand in the world for the treatment of COVID-19 patients
Eskayef Oncology manufacturing plant receives ANVISA Brazil Approval, which is the 1st and only ANVISA certified Oncology Facility in Bangladesh